1: Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2012 Mar; 55(3): 343-50.
Die spezifische Immuntherapie (Hyposensibilisierung) mit Allergenen zwischen wissenschaftlichem Fortschritt und medizinischer Versorgungsrealitat. Eine Standortbestimmung. Kleine-Tebbe, J; Ackermann-Simon, J; Hanf, G; Allergie- und Asthma-Zentrum Westend, Praxis Hanf, Ackermann u. Kleine-Tebbe, Spandauer Damm 130, Haus 9, 14050, Berlin, Deutschland. firstname.lastname@example.org Allergen-specific immunotherapy (SIT, desensitization) is applied monthly with subcutaneous injections (SCIT) or sublingually (SLIT) with droplets or tablets on a daily basis. Numerous immunological changes during SIT induce long-lasting tolerance. Efficacy has been demonstrated by a number of controlled studies for insect venom hypersensitivity (SCIT), allergic rhinoconjunctivitis (SCIT, SLIT particularly in grass pollen allergy), and allergic asthma (SCIT > SLIT). SIT is indicated in children and adults with severe allergic reactions from insect venoms (e.g., bee, wasp) or cumbersome symptoms from pollen, house dust mites or mold allergens and proven immediated-type allergy. Contraindications must be considered individually. SIT is performed for 3 years, in case of venom allergy 3-5 years. Severe systemic reactions are rare after SCIT. After SLIT rather local allergic symptoms of short duration occur in the mouth and throat. At present, the number prescriptions for SIT has decreased due to inadequate reimbursement of allergy-related services (diagnostics, therapies, monitoring). In the future, inferior medical care of allergic patients in Germany is expected, who until now have benefited from the preventive effects of SIT (reduced risk of developing asthma and new allergic sensitizations).